Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2026-02-25 @ 4:57 PM
Study NCT ID:
NCT05386550
Status:
TERMINATED
Last Update Posted:
2025-06-13
First Post:
2022-05-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MS202359_0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |